Natural combination hormone replacement formulations and therapies
Estrogen and progesterone replacement therapies are provided herein. Among others, the following formulations are provided herein: solubilized estradiol without progesterone; micronized progesterone without estradiol; micronized progesterone with partially solubilized progesterone; solubilized estradiol with micronized progesterone; solubilized estradiol with micronized progesterone in combination with partially solubilized progesterone; and solubilized estradiol with solubilized progesterone.
1. A method of treating a menopause symptom in a woman with a uterus comprising: administering an effective amount of a pharmaceutical composition, the pharmaceutical composition comprising:
a solubilizing agent comprising:
mono- and diglycerides of capric and caprylic acid; and
at least one of lauroyl macrogol-32 glycerides EP, lauroyl polyoxyl-32 glycerides NF, or lauroyl polyoxylglycerides;
progesterone, wherein the progesterone is micronized and partially solubilized; and
estradiol, the estradiol being at least about 90% solubilized in the solubilizing agent;
wherein the estradiol and the progesterone are present in the solubilizing agent, and the micronized progesterone is uniformly dispersed.
2. The method of claim 1 , wherein the ratio of progesterone to estradiol is from about 24:1 to about 200:1.
3. The method of claim 2 , wherein the ratio of progesterone to estradiol comprises one of: about 24:1, about 25:1, about 96:1, about 100:1, about 192:1, and about 200:1.
4. The method of claim 1 , wherein the progesterone is between about 7.14% w/w and about 33.33% w/w of the pharmaceutical composition.
5. The method of claim 1 , wherein the estradiol is between about 0.12% w/w and about 0.35% w/w of the pharmaceutical composition.
6. The method of claim 1 , wherein the composition is encapsulated in a gelatin capsule; and
wherein each gelatin capsule comprises from about 25 mg to about 200 mg of progesterone and from about 0.125 mg to about 2.00 mg of estradiol.
7. The method of claim 1 , wherein the estradiol is at least 95% solubilized in the solubilizing agent.
8. A method of treating a menopause symptom in a woman with a uterus comprising: administering an effective amount of a pharmaceutical composition, the pharmaceutical composition comprising:
a solubilizing agent comprising:
monoglycerides and diglycerides of caprylic and capric acid; and
a polyethylene glycol glyceride;
progesterone, wherein the progesterone is micronized and partially solubilized; and
estradiol, the estradiol being at least about 90% solubilized in the solubilizing agent;
wherein the estradiol and the progesterone are present in the solubilizing agent, and the micronized progesterone is uniformly dispersed.
9. The method of claim 8 , wherein the ratio of progesterone to estradiol is from about 24:1 to about 200:1.
10. The method of claim 9 , wherein the ratio of progesterone to estradiol comprises one of: about 24:1, about 25:1, about 96:1, about 100:1, about 192:1 and about 200:1.
11. The method of claim 8 , wherein the progesterone is between about 7.14% w/w and about 33.33% w/w of the pharmaceutical composition.
12. The method of claim 8 , wherein the estradiol is between about 0.12% w/w and about 0.35% w/w of the pharmaceutical composition.
13. The method of claim 8 , wherein the composition is encapsulated in a gelatin capsule; and
wherein each gelatin capsule comprises from about 25 mg to about 200 mg of progesterone and from about 0.125 mg to about 2.00 mg of estradiol.
14. The method of claim 8 , wherein the estradiol is at least 95% solubilized in the solubilizing agent.
15. A method of treating a menopause symptom in a woman with a uterus comprising: administering an effective amount of a pharmaceutical composition, the pharmaceutical composition comprising:
a solubilizing agent comprising:
mono- and diglycerides of capric and caprylic acid; and
at least one of lauroyl macrogol-32 glycerides, lauroyl polyoxyl-32 glycerides, and lauroyl polyoxylglycerides;
progesterone, wherein the progesterone is micronized and partially solubilized; and
estradiol, the estradiol being at least about 90% solubilized in the solubilizing agent;
wherein the estradiol and the progesterone are present in the solubilizing agent, and the micronized progesterone is uniformly dispersed; and
wherein the ratio of progesterone to estradiol is from about 24:1 to about 200:1.
16. The method of claim 15 , wherein the ratio of progesterone to estradiol comprises one of: about 24:1, about 25:1, about 96:1, about 100:1, about 192:1 and about 200:1.
17. The method of claim 15 , wherein the progesterone is between about 7.14% w/w and about 33.33% w/w of the pharmaceutical composition.
18. The method of claim 15 , wherein the estradiol is between about 0.12% w/w and about 0.35% w/w of the pharmaceutical composition.
19. The method of claim 15 , wherein the composition is encapsulated in a gelatin capsule; and
wherein each gelatin capsule comprises from about 25 mg to about 200 mg of progesterone and from about 0.125 mg to about 2.00 mg of estradiol.
20. A method of treating a menopause symptom in a woman with a uterus comprising: administering an effective amount of a pharmaceutical composition that comprises progesterone, estradiol and a solubilizing agent;
wherein the solubilizing agent comprises mono- and diglycerides of capric and caprylic acid, and at least one of lauroyl macrogol-32 glycerides, lauroyl polyoxyl-32 glycerides, and lauroyl polyoxylglycerides;
wherein the progesterone is micronized and partially solubilized;
wherein the estradiol is at least about 90% solubilized in the solubilizing agent;
wherein the estradiol and the progesterone are present in the solubilizing agent, and the micronized progesterone is uniformly dispersed;
wherein the composition is encapsulated in a gelatin capsule; and
wherein each gelatin capsule comprises from about 25 mg to about 200 mg of progesterone and from about 0.125 mg to about 2.00 mg of estradiol.